India, March 26 -- Shares of Praxis Precision Medicines, Inc. (PRAX) jumped over 26% on Tuesday morning after the company reported positive results from a phase 2 study of epilepsy treatment.
PRAX is currently trading at $63.85, up $13.35 or 26.44%, on the Nasdaq. The stock opened its trading at $60.55 after closing Monday at $50.50. The stock has traded between $11.85 and $67.21 in the past 52-week period.
Praxis Precision Medicines issued an update on Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with Photo Paroxysmal Response, or PPR. In the 45 mg cohort, 100% of patients achieved a complete response. In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, the co...